RAAS is one of the most important systems in med-surg because it sits underneath blood pressure, fluid balance, heart failure, kidney disease, potassium abnormalities, and many of the meds you give every shift. ACE inhibitors, ARBs, ARNIs, and mineralocorticoid receptor antagonists are all tied to it.
1) The trigger: when RAAS turns on
In plain English: the kidneys think the body is underfilled or underpressured, so they start a hormone cascade to raise pressure and hold onto sodium/water.
That is why a patient can look fluid overloaded overall but still have RAAS activated if the kidneys sense poor effective perfusion, especially in heart failure. RAAS-blocking drugs are central to heart failure management for exactly this reason.
2) The sequence itself
3) The big physiologic effects
Know what angiotensin II and aldosterone actually do.
In heart failure
RAAS turns on because the kidneys interpret poor forward flow as low volume, even when the patient is overloaded. The result is more sodium/water retention, more vasoconstriction, more afterload, and more congestion. That is why ACE inhibitors, ARBs, ARNIs, and aldosterone antagonists are used to help reduce progression and improve outcomes in appropriate HF patients.
In hypertension
RAAS contributes to chronic vasoconstriction and sodium retention. Blocking it lowers BP and reduces cardiac workload. The American Heart Association notes ACE inhibitors and ARBs lower blood pressure by widening blood vessels and are used in heart failure as well.
In CKD
RAAS can initially help preserve filtration pressure, but chronic activation contributes to kidney damage and proteinuria. RAAS blockade is a major CKD strategy, especially when albuminuria is present. KDIGO continues to recommend RAAS inhibition in appropriate CKD patients and emphasizes monitoring creatinine and potassium after starting or increasing therapy.
In cirrhosis or other low-effective-volume states
Total body fluid may be high, but the kidneys sense underfilling, so RAAS stays activated. This helps explain edema and ascites physiology.
You should know these as a clean framework.
ACE inhibitors
ARBS
ARNIs
Mineralocorticoid receptor antagonists
These drug classes are core parts of heart failure management in guideline-based care.
Labs and Monitoring
1) Why creatinine may rise after starting ACEi/ARB
Angiotensin II helps maintain intraglomerular pressure by constricting the efferent arteriole. When you block RAAS, GFR can drop somewhat, so creatinine may rise.
That does not automatically mean the drug is wrong. KDIGO states ACEi/ARB therapy is generally continued unless serum creatinine rises bymore than 30% within 4 weeks of initiation or dose increase, while potassium/BP/volume status are also assessed.
2) Hyperkalemia risk
ABecause aldosterone normally helps excrete potassium, RAAS blockade can cause potassium retention. Hyperkalemia risk rises further with:
3) Why you should care about NSAIDs
NSAIDs can reduce renal perfusion and worsen kidney injury risk, especially when combined with:
That combination is one reason a patient’s creatinine suddenly worsens.
4) Why aldosterone antagonists can be dangerous if you are not watching labs
Spironolactone is great in the right patient, but if renal function worsens or potassium is already high, it can become risky fast.
Ask yourself:
Tier 1: core physiology
Tier 2: organ-system application
Tier 3: medication mastery
Tier 4: monitoring
1) RAAS is a compensation system, not always a helpful one. It helps short term, but chronic activation often worsens HF, HTN, and CKD.
2) Fluid overloaded does not mean kidneys feel well perfused. This is why HF physiology confuses people. Heart failure patients can be overloaded AND have RAAS activated This is a huge concept. Even if the patient has: edema, crackles, weight gain, JVD… the kidneys may still think perfusion is low. So RAAS stays on and makes the overload worse.
3) A mild creatinine bump after ACEi/ARB can be expected. Why? Because angiotensin II normally constricts the efferent arteriole to help maintain glomerular pressure.
**Important** A small rise may be expected. A big rise should make you think: AKI, dehydration, overdiuresis, renal artery stenosis, or NSAID-related kidney injury.
4) Hyperkalemia is one of the biggest RAAS-blocker nursing dangers. Hyperkalemia risk is higher especially with CKD, AKI, supplements, spironolactone, and NSAIDs. Why? Because aldosterone normally helps the body excrete potassium. If you block RAAS: less aldosterone effect, more potassium retained.
5) ACEi cough and angioedema are not random trivia. They matter clinically.
6) NSAIDs can worsen the situation. NSAIDs can reduce renal perfusion and increase risk of kidney injury, especially in patients on: ACE inhibitors, ARBs, and diuretics.
It means that when you see:
Study checklist
What is RAAS?
RAAS = Renin-Angiotensin-Aldosterone System
It is the body’s major hormone system for:
When does RAAS turn on? The kidneys activate RAAS when they sense:
The RAAS Cascade
Memorize this sequence:
Liver releases angiotensinogen
↓
Kidney releases renin
↓
Renin converts angiotensinogen → angiotensin I
↓
ACE converts angiotensin I → angiotensin II
↓
Angiotensin II: vasoconstricts, stimulates aldosterone, increases ADH/thirst, helps maintain GFR by constricting the efferent arteriole
Aldosterone does what?
1) Heart failure
In HF, kidneys sense poor perfusion, even if the patient is fluid overloaded.
2) Hypertension
3) CKD RAAS may temporarily help maintain GFR, but chronic activation damages kidneys over time.